TTK Healthcare Ltd
- Market Cap ₹ 1,660 Cr.
- Current Price ₹ 1,175
- High / Low ₹ 1,595 / 991
- Stock P/E 23.5
- Book Value ₹ 768
- Dividend Yield 0.85 %
- ROCE 9.26 %
- ROE 6.89 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 42.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%
Cons
- The company has delivered a poor sales growth of 4.42% over past five years.
- Earnings include an other income of Rs.67.6 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Diversified Diversified Diversified Diversified
Part of BSE SmallCap BSE Allcap BSE Industrials
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 416 | 483 | 519 | 528 | 578 | 628 | 646 | 476 | 599 | 725 | 753 | 801 | 825 | |
| 396 | 453 | 478 | 489 | 535 | 578 | 617 | 457 | 577 | 694 | 715 | 767 | 797 | |
| Operating Profit | 20 | 30 | 40 | 38 | 43 | 50 | 28 | 19 | 22 | 31 | 37 | 35 | 28 | 
| OPM % | 5% | 6% | 8% | 7% | 7% | 8% | 4% | 4% | 4% | 4% | 5% | 4% | 3% | 
| 6 | 7 | 6 | 6 | 8 | 8 | 9 | 28 | 42 | 643 | 63 | 85 | 68 | |
| Interest | 3 | 4 | 3 | 3 | 5 | 3 | 3 | 2 | 3 | 5 | 3 | 3 | 3 | 
| Depreciation | 3 | 6 | 7 | 12 | 15 | 15 | 14 | 13 | 13 | 13 | 13 | 8 | 9 | 
| Profit before tax | 20 | 26 | 36 | 29 | 30 | 39 | 19 | 32 | 48 | 657 | 84 | 108 | 83 | 
| Tax % | 37% | 39% | 36% | 36% | 40% | 38% | 37% | -44% | 13% | 3% | 25% | 25% | |
| 12 | 16 | 23 | 19 | 18 | 24 | 12 | 46 | 42 | 640 | 63 | 82 | 66 | |
| EPS in Rs | 15.95 | 20.81 | 29.19 | 24.13 | 12.86 | 17.25 | 8.72 | 32.87 | 29.43 | 452.72 | 44.47 | 57.79 | 46.90 | 
| Dividend Payout % | 25% | 22% | 17% | 21% | 39% | 29% | 34% | 18% | 34% | 2% | 22% | 17% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% | 
| 5 Years: | 4% | 
| 3 Years: | 10% | 
| TTM: | 7% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% | 
| 5 Years: | 42% | 
| 3 Years: | 22% | 
| TTM: | 9% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% | 
| 5 Years: | 22% | 
| 3 Years: | 11% | 
| 1 Year: | -23% | 
| Return on Equity | |
|---|---|
| 10 Years: | 23% | 
| 5 Years: | 26% | 
| 3 Years: | 29% | 
| Last Year: | 7% | 
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 
| Reserves | 99 | 110 | 128 | 150 | 219 | 237 | 235 | 281 | 316 | 939 | 987 | 1,051 | 1,071 | 
| 32 | 42 | 38 | 23 | 47 | 29 | 30 | 19 | 22 | 27 | 23 | 24 | 27 | |
| 102 | 115 | 128 | 104 | 127 | 136 | 152 | 180 | 207 | 189 | 183 | 192 | 184 | |
| Total Liabilities | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,206 | 1,281 | 1,296 | 
| 54 | 52 | 106 | 99 | 110 | 98 | 89 | 85 | 80 | 71 | 75 | 81 | 78 | |
| CWIP | 2 | 46 | 1 | 0 | 1 | 2 | 9 | 0 | 0 | 3 | 1 | 0 | 0 | 
| Investments | 0 | 0 | 10 | 9 | 9 | 13 | 9 | 13 | 15 | 13 | 13 | 11 | 12 | 
| 184 | 177 | 185 | 177 | 288 | 304 | 325 | 395 | 463 | 1,083 | 1,118 | 1,189 | 1,205 | |
| Total Assets | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,206 | 1,281 | 1,296 | 
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | 39 | 37 | 18 | 25 | 17 | 20 | 96 | 45 | -25 | -5 | -4 | |
| -15 | -49 | -27 | 5 | -22 | 10 | -13 | -77 | -30 | 32 | 28 | 20 | |
| 2 | 3 | -11 | -23 | -7 | -31 | -10 | -17 | -10 | -12 | -22 | -18 | |
| Net Cash Flow | 0 | -7 | -0 | 0 | -4 | -4 | -4 | 2 | 5 | -6 | 2 | -2 | 
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 34 | 34 | 33 | 24 | 35 | 47 | 43 | 46 | 33 | 46 | 42 | 41 | 
| Inventory Days | 64 | 62 | 66 | 65 | 80 | 77 | 101 | 123 | 102 | 89 | 105 | 107 | 
| Days Payable | 56 | 50 | 53 | 100 | 130 | 101 | 121 | 170 | 134 | 116 | 110 | 106 | 
| Cash Conversion Cycle | 41 | 46 | 46 | -11 | -16 | 22 | 23 | -2 | 1 | 19 | 36 | 43 | 
| Working Capital Days | -24 | -31 | -38 | -24 | -30 | -6 | -3 | -32 | -28 | 4 | 49 | 48 | 
| ROCE % | 17% | 20% | 23% | 18% | 15% | 15% | 8% | 6% | 8% | 10% | 9% | 9% | 
Documents
Announcements
- 
        
          Outcome Of The Board Meeting Held On October 17, 2025
          
            17 Oct - Q2/H1 FY2025 results: Q2 revenue Rs20,356.77 lakhs; Q2 PAT Rs2,038.64 lakhs; RPT policy amended Oct 17, 2025.
- 
        
          Board Meeting Outcome for Outcome Of The Board Meeting Held On October 17, 2025
          
            17 Oct - Board approved unaudited Q2/H1 results (30 Sep 2025): H1 income Rs42,999.75 lakh; H1 PAT Rs3,338.58 lakh; RPT policy amended.
- 
        
          Intimation Of Death Of Mr. T T Jagannathan, Belonging To The Promoter And Promoter Group Of The Company Under Regulation 30 And 31A Of The SEBI LODR Regulations 2015
          
            10 Oct - Promoter T T Jagannathan died Oct 09, 2025; held 7,59,298 shares (5.37%); partner with 3%.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct
- 
        
          Board Meeting Intimation for Meeting Of The Board To Be Held On October 17, 2025
          
            25 Sep - Board meeting on Oct 17, 2025 to approve Q2 results; trading window closed Oct 1–19, 2025.
Annual reports
- 
    
      Financial Year 2025
      from bse
- 
    
      Financial Year 2024
      from bse
- 
    
      Financial Year 2023
      from bse
- 
    
      Financial Year 2022
      from bse
- 
    
      Financial Year 2021
      from bse
- 
    
      Financial Year 2020
      from bse
- 
    
      Financial Year 2019
      from bse
- 
    
      Financial Year 2018
      from bse
- 
    
      Financial Year 2017
      from bse
- 
    
      Financial Year 2016
      from bse
- 
    
      Financial Year 2015
      from bse
- 
    
      Financial Year 2014
      from bse
- 
    
      Financial Year 2013
      from bse
- 
    
      Financial Year 2012
      from bse
- 
    
      Financial Year 2011
      from bse
Concalls
- 
      Sep 2016TranscriptNotesPPT
Business Segments FY24
1. Consumer Products (~31% revenue, 29% Op. profit): The company markets and distributes products that transcend categories; baby care (Woodward’s Gripe Water), personal care (Eva Deodrants), home care- room & air fresheners (Good Home ), and sexual wellness (Skore).. [1] The Woodward's Gripe Water is one of the oldest FMCG brands worldwide and is a market leader in the Indian colic market. It has been marketed in India since 1928. It has a distribution network of 27 warehouses, 2,600+ distributors, 650+ frontline sales teams, and a reach of ~4 lakh outlets across India. [2]